Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 158.15 Million EUR | -19.45% |
| 2022 | 196.34 Million EUR | -14.57% |
| 2021 | 229.83 Million EUR | -14.87% |
| 2020 | 269.96 Million EUR | 214.57% |
| 2019 | 85.81 Million EUR | -47.08% |
| 2018 | 162.16 Million EUR | -9.58% |
| 2017 | 179.33 Million EUR | -0.89% |
| 2016 | 180.94 Million EUR | -6.16% |
| 2015 | 192.81 Million EUR | 29.68% |
| 2014 | 148.68 Million EUR | 5.84% |
| 2013 | 140.47 Million EUR | 1.63% |
| 2012 | 138.22 Million EUR | -9.35% |
| 2011 | 152.48 Million EUR | -0.67% |
| 2010 | 153.5 Million EUR | 24.41% |
| 2009 | 123.38 Million EUR | 17.22% |
| 2008 | 105.26 Million EUR | 23.17% |
| 2007 | 85.45 Million EUR | 12.09% |
| 2006 | 76.24 Million EUR | 16086.84% |
| 2005 | 471 Thousand EUR | -29.6% |
| 2004 | 669 Thousand EUR | -99.17% |
| 2003 | 80.33 Million EUR | 21.95% |
| 2002 | 65.87 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 37.96 Million EUR | -6.28% |
| 2024 Q3 | 45.65 Million EUR | 6.49% |
| 2024 Q2 | 42.87 Million EUR | 12.92% |
| 2023 FY | 158.15 Million EUR | -19.45% |
| 2023 Q4 | 40.51 Million EUR | 8.16% |
| 2023 Q3 | 37.45 Million EUR | -18.95% |
| 2023 Q2 | 46.21 Million EUR | 36.0% |
| 2023 Q1 | 33.97 Million EUR | -38.16% |
| 2022 FY | 196.34 Million EUR | -14.57% |
| 2022 Q1 | 53.18 Million EUR | -38.08% |
| 2022 Q2 | 48.24 Million EUR | -9.28% |
| 2022 Q4 | 54.94 Million EUR | 37.47% |
| 2022 Q3 | 39.96 Million EUR | -17.17% |
| 2021 Q3 | 45.25 Million EUR | -4.6% |
| 2021 FY | 229.83 Million EUR | -14.87% |
| 2021 Q1 | 51.26 Million EUR | 7.23% |
| 2021 Q2 | 47.43 Million EUR | -7.47% |
| 2021 Q4 | 85.88 Million EUR | 89.81% |
| 2020 FY | 269.96 Million EUR | 214.57% |
| 2020 Q1 | 99.45 Million EUR | 325.98% |
| 2020 Q3 | 53.04 Million EUR | -23.85% |
| 2020 Q4 | 47.8 Million EUR | -9.88% |
| 2020 Q2 | 69.65 Million EUR | -29.96% |
| 2019 Q2 | 21.96 Million EUR | 13.0% |
| 2019 Q4 | 23.34 Million EUR | 10.83% |
| 2019 Q1 | 19.43 Million EUR | -32.4% |
| 2019 Q3 | 21.06 Million EUR | -4.1% |
| 2019 FY | 85.81 Million EUR | -47.08% |
| 2018 Q1 | 44.57 Million EUR | 14.48% |
| 2018 Q4 | 28.75 Million EUR | 8.73% |
| 2018 Q2 | 62.38 Million EUR | 39.95% |
| 2018 Q3 | 26.44 Million EUR | -57.6% |
| 2018 FY | 162.16 Million EUR | -9.58% |
| 2017 Q1 | 45.47 Million EUR | 10.04% |
| 2017 Q4 | 38.93 Million EUR | -10.45% |
| 2017 FY | 179.33 Million EUR | -0.89% |
| 2017 Q3 | 43.47 Million EUR | -15.5% |
| 2017 Q2 | 51.45 Million EUR | 13.15% |
| 2016 Q4 | 41.32 Million EUR | -12.98% |
| 2016 FY | 180.94 Million EUR | -6.16% |
| 2016 Q2 | 49.95 Million EUR | 18.45% |
| 2016 Q3 | 47.48 Million EUR | -4.94% |
| 2016 Q1 | 42.17 Million EUR | -36.09% |
| 2015 Q1 | 34.96 Million EUR | 10.03% |
| 2015 FY | 192.81 Million EUR | 29.68% |
| 2015 Q4 | 65.99 Million EUR | 55.44% |
| 2015 Q3 | 42.45 Million EUR | -14.06% |
| 2015 Q2 | 49.4 Million EUR | 41.28% |
| 2014 Q4 | 31.77 Million EUR | -17.84% |
| 2014 FY | 148.68 Million EUR | 5.84% |
| 2014 Q3 | 38.67 Million EUR | -12.14% |
| 2014 Q2 | 44.02 Million EUR | 28.67% |
| 2014 Q1 | 34.21 Million EUR | 9.54% |
| 2013 Q3 | 37.93 Million EUR | -6.32% |
| 2013 Q4 | 31.23 Million EUR | -17.67% |
| 2013 FY | 140.47 Million EUR | 1.63% |
| 2013 Q1 | 30.81 Million EUR | -52.93% |
| 2013 Q2 | 40.49 Million EUR | 31.41% |
| 2012 Q3 | 36.77 Million EUR | -11.25% |
| 2012 FY | 138.22 Million EUR | -9.35% |
| 2012 Q1 | 31.31 Million EUR | -56.0% |
| 2012 Q2 | 41.44 Million EUR | 32.32% |
| 2012 Q4 | 65.47 Million EUR | 78.03% |
| 2011 Q1 | 35.41 Million EUR | 5.77% |
| 2011 Q4 | 71.18 Million EUR | 80.69% |
| 2011 FY | 152.48 Million EUR | -0.67% |
| 2011 Q3 | 39.39 Million EUR | -14.15% |
| 2011 Q2 | 45.88 Million EUR | 29.55% |
| 2010 Q1 | 32.94 Million EUR | 16.83% |
| 2010 Q2 | 45.79 Million EUR | 38.99% |
| 2010 FY | 153.5 Million EUR | 24.41% |
| 2010 Q3 | 41.28 Million EUR | -9.84% |
| 2010 Q4 | 33.48 Million EUR | -18.89% |
| 2009 Q3 | 34.98 Million EUR | -8.19% |
| 2009 Q1 | 22.08 Million EUR | -1.91% |
| 2009 Q2 | 38.1 Million EUR | 72.52% |
| 2009 FY | 123.38 Million EUR | 17.22% |
| 2009 Q4 | 28.2 Million EUR | -19.4% |
| 2008 Q4 | 22.51 Million EUR | -21.18% |
| 2008 Q3 | 28.56 Million EUR | -12.91% |
| 2008 Q2 | 32.8 Million EUR | 53.52% |
| 2008 Q1 | 21.36 Million EUR | 0.0% |
| 2008 FY | 105.26 Million EUR | 23.17% |
| 2007 FY | 85.45 Million EUR | 12.09% |
| 2006 FY | 76.24 Million EUR | 16086.84% |
| 2005 FY | 471 Thousand EUR | -29.6% |
| 2004 FY | 669 Thousand EUR | -99.17% |
| 2003 FY | 80.33 Million EUR | 21.95% |
| 2002 FY | 65.87 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -902.682% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -636.349% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -240517.393% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -768.114% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -28.628% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 645.81 Thousand USD | -24389.091% |
| Genus plc | 668.8 Million USD | 76.353% |
| Pharming Group N.V. | 245.31 Million USD | 35.531% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -159660.187% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -38458.385% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -205933.012% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -400104.97% |
| ONE Bio Corp. | 52.29 Million USD | -202.418% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -218.081% |
| Mesoblast Limited | 5.9 Million USD | -2579.651% |
| MultiCell Technologies, Inc. | 49.32 USD | -320666972.182% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -434.355% |
| Genscript Biotech Corporation | 839.52 Million USD | 81.162% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -897425.68% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -28257.569% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -225832.857% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -208754.524% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -23917.16% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -323321.268% |
| Q BioMed Inc. | 284.35 Thousand USD | -55518.74% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 98.923% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -8.996% |
| Enzolytics Inc. | 52.79 Thousand USD | -299454.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -25889.565% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 87.103% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -8085.973% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -15831031.131% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -112671.495% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -25516.634% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -15751.346% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -227.073% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -847.852% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -66755.343% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -66755.343% |
| Affymax, Inc. | 1.36 Million USD | -11452.447% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -1930.466% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -33284.628% |
| SYBLEU INC | 11.69 Thousand USD | -1352097.332% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1216461.538% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -399943.001% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -4649.339% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -2272.888% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -15121.655% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -513.781% |
| CSL Limited | 14.8 Billion USD | 98.931% |
| Cellectis S.A. | 755 Thousand USD | -20847.417% |